Charles Schwab Investment Management Inc. Sells 29,332 Shares of InMode Ltd. (NASDAQ:INMD)

Charles Schwab Investment Management Inc. reduced its position in shares of InMode Ltd. (NASDAQ:INMD) by 13.8% during the 4th quarter, HoldingsChannel reports. The firm owned 183,777 shares of the healthcare company’s stock after selling 29,332 shares during the period. Charles Schwab Investment Management Inc.’s holdings in InMode were worth $3,069,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Systematic Financial Management LP increased its stake in shares of InMode by 13.3% during the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock valued at $16,647,000 after buying an additional 115,492 shares during the period. Barclays PLC increased its position in InMode by 113.5% during the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock valued at $2,876,000 after purchasing an additional 90,173 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of InMode by 54.1% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,480 shares of the healthcare company’s stock valued at $2,127,000 after purchasing an additional 44,058 shares in the last quarter. State Street Corp lifted its position in shares of InMode by 3.7% in the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock worth $34,657,000 after purchasing an additional 73,183 shares during the period. Finally, Atlas Legacy Advisors LLC bought a new position in shares of InMode during the fourth quarter valued at approximately $848,000. 68.04% of the stock is owned by institutional investors.

InMode Trading Up 0.5 %

Shares of INMD opened at $18.30 on Friday. The firm has a market cap of $1.27 billion, a PE ratio of 7.79 and a beta of 2.08. InMode Ltd. has a 12 month low of $14.87 and a 12 month high of $21.92. The stock has a fifty day moving average price of $18.30 and a 200-day moving average price of $17.75.

Analyst Upgrades and Downgrades

INMD has been the subject of a number of analyst reports. Barclays upped their target price on InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 5th. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $22.25.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.